private:cartiheal
|
1031481
|
Nov 18th, 2019 12:00AM
|
CartiHeal
|
669
|
21.00
|
Open
|
Medical Device
|
Nov 18th, 2019 03:58PM
|
Nov 18th, 2019 03:58PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 17th, 2019 12:00AM
|
CartiHeal
|
669
|
21.00
|
Open
|
Medical Device
|
Nov 17th, 2019 04:23PM
|
Nov 17th, 2019 04:23PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 16th, 2019 12:00AM
|
CartiHeal
|
669
|
21.00
|
Open
|
Medical Device
|
Nov 16th, 2019 04:18PM
|
Nov 16th, 2019 04:18PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 15th, 2019 12:00AM
|
CartiHeal
|
668
|
21.00
|
Open
|
Medical Device
|
Nov 15th, 2019 12:54PM
|
Nov 15th, 2019 12:54PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 13th, 2019 12:00AM
|
CartiHeal
|
667
|
21.00
|
Open
|
Medical Device
|
Nov 13th, 2019 01:18PM
|
Nov 13th, 2019 01:18PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 12th, 2019 12:00AM
|
CartiHeal
|
666
|
21.00
|
Open
|
Medical Device
|
Nov 12th, 2019 03:01PM
|
Nov 12th, 2019 03:01PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 11th, 2019 12:00AM
|
CartiHeal
|
665
|
21.00
|
Open
|
Medical Device
|
Nov 11th, 2019 02:59PM
|
Nov 11th, 2019 02:59PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 10th, 2019 12:00AM
|
CartiHeal
|
665
|
21.00
|
Open
|
Medical Device
|
Nov 10th, 2019 06:05PM
|
Nov 10th, 2019 06:05PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 9th, 2019 12:00AM
|
CartiHeal
|
666
|
21.00
|
Open
|
Medical Device
|
Nov 9th, 2019 05:32PM
|
Nov 9th, 2019 05:32PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|
private:cartiheal
|
1031481
|
Nov 8th, 2019 12:00AM
|
CartiHeal
|
666
|
21.00
|
Open
|
Medical Device
|
Nov 8th, 2019 02:43PM
|
Nov 8th, 2019 02:43PM
|
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
|
Open
|
|
Open
|
17 Atir Yeda
|
Kfar Saba
|
Israel
|
IL
|
4464313
|
|
CartiHeal
|
|
Pharmaceuticals & Biotechnology
|